



(51) International Patent Classification:
A61K 38/08 (2019.01) *C07K 14/47* (2006.01)
C07K 7/06 (2006.01)

(21) International Application Number:
PCT/US2019/057876

(22) International Filing Date:
24 October 2019 (24.10.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/749,861 24 October 2018 (24.10.2018) US

(71) Applicant: **ALLYSTA PHARMACEUTICALS, INC.**
[US/US]; 400 Concar Drive, San Mateo, California 94402
(US).

(72) Inventors: **BARMAN, Shikha P.**; 2 Bonnievale Dr., Bedford, Massachusetts 01730 (US). **WARD, Kevin L.**; 106 Claremont Ave, Arlington, Massachusetts 02476 (US). **CHEN, Yugang**; 15 Arthur St, Winchester, Massachusetts 01890 (US).

(74) Agent: **SUN-HOFFMAN, Lin**; P.O. Box 52048, Palo Alto, California 94303 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ADIPONECTIN PEPTIDOMIMETICS FORMULATIONS




FIG. 1

(57) Abstract: Disclosed are compositions and methods for the use of adiponectin peptidomimetics in therapeutic applications. The compositions can include a peptide, for example, D-Asn-Ile-Pro-Nva-Leu-Tyr-D-Ser-Phe-Ala-D-Ser-NH₂, a solubilizer, a surfactant(s), a buffer, optionally boric acid and optionally mannitol. The osmolality of the composition can be between 260 to 330 mOsm/kg and the pH can be between 4.5 to 5.5. Methods of using the compositions in treating certain eye disease(s) are also disclosed.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*